UK markets close in 2 hours 53 minutes

SCYNEXIS, Inc. (0L49.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.5100-0.0550 (-3.51%)
As of 06:11PM BST. Market open.

SCYNEXIS, Inc.

1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302-6548
United States
201 884 5485
https://www.scynexis.com

Sector(s)
Industry
Full-time employees29

Key executives

NameTitlePayExercisedYear born
Mr. David Gonzalez Angulo M.D.CEO, President & Director631.69kN/A1965
Mr. Scott Sukenick J.D.Chief Legal Officer & Corporate Secretary542.05kN/A1978
Mr. Ivor Macleod CPA, M.B.A.Chief Financial OfficerN/AN/A1961
Debbie EtchisonExecutive Director of CommunicationsN/AN/AN/A
Ms. Daniella GiganteVice President of Human Resources & Information TechnologyN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Corporate governance

SCYNEXIS, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.